Results 1 to 10 of about 110,931 (189)

Bevacizumab in the therapy for refractory metastatic colorectal cancer

Biologics: Targets & Therapy, 2008
Mary F MulcahyNorthwestern University, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago IL, USAAbstract: Colorectal cancer is the second most common cause of cancer related deaths in the United States.
Mary F Mulcahy
doaj   +1 more source

Bevacizumab (Avastin) and Thermal Laser Combination Therapy for Peripapillary Choroidal Neovascular Membranes

Journal of Ophthalmology, 2017
Objective. This is a retrospective interventional case series describing the results of 5 eyes from 5 patients with symptomatic peripapillary choroidal neovascularization (CNVM) receiving initial bevacizumab treatment followed by thermal laser and ...
Sean D. Adrean, Scott Grant, Siyang Chaili   +2 more
doaj   +1 more source

Bevacizumab for the Treatment of Recurrent Glioblastoma

Clinical Medicine Insights: Oncology, 2011
Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death.
Marc C. Chamberlain
doaj   +1 more source

Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients

Cancer Immunology, Immunotherapy
Background Interstitial pneumonitis (IP) is a severe adverse event in patients receiving immunotherapy. Although PD-1/PD-L1 inhibitors and bevacizumab have been widely used in patients with non-small cell lung cancer (NSCLC), the interaction between ...
Linling Wang, Yasi Xu, Yanyan Zhao, Bing Xia, Lucheng Zhu   +4 more
doaj   +1 more source

Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study

World Journal of Surgical Oncology
Objective The clinical benefits of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients are controversial. This study intended to evaluate the efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in these ...
Bin Yin, Wei Luo
doaj   +1 more source

Intravitreal bevacizumab

Indian Journal of Ophthalmology, 2018
openaire   +3 more sources

Comparative efficacy of therapeutic strategies for recurrent or refractory glioblastoma: a systematic review and network meta-analysis. [PDF]

Front Neurol
Zhang H, Sun L, Yun Z, Yin X, Li Y, Wu J, Dong G.   +6 more
europepmc   +1 more source

Biopsy-proven kidney-limited thrombotic microangiopathy associated with bevacizumab and pegylated liposomal doxorubicin: a case with a biphasic clinical course. [PDF]

CEN Case Rep
Chigusa N, Azegami T, Nakayama T, Yoshimoto N, Hishikawa A, Hagiwara A, Hashiguchi A, Hayashi K.   +7 more
europepmc   +1 more source

Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab. [PDF]

J Neurooncol
Loxterkamp E, Luo A, Sanvito F, Le CT, Raymond C, Yang C, Prins TJ, Fisher A, Salamon N, Liau LM, Chong RA, Nghiemphu PL, Nathanson DA, Cloughesy TF, Lai A, Ellingson BM.   +15 more
europepmc   +1 more source

Post-Recurrence Outcomes Associated with a Bevacizumab-Containing First-Recurrence Strategy in Glioblastoma: A Propensity-Weighted Single-Center Cohort Study with Competing-Risk Analysis. [PDF]

Cancers (Basel)
Yeşilbaş E, Göksu SS.
europepmc   +1 more source